Abstract
A battery of proinflammatory agents triggers the activation of NF-κB. This inducible transcription factor participates in the expression of an exceptionally large number of target genes, many of them contributing to the regulation of innate and adaptive immunity. Since some target genes also function as NF-κB activators, activation of this transcription factor allows the establishment of a signal amplification loop. Dysregulation of the NF-κB system and hyperactivated expression of inflammatory mediators are often found in association with some autoimmune diseases, which occur upon mounting of the adaptive immune response against self-antigens. In this review we summarize the relevance of aberrant NF-κB signaling for the development and perpetuation of some autoimmune diseases such as rheumatoid arthritis, diabetes mellitus type 1 and Crohns disease. The assets and drawbacks of systemic or cell-type specific NF-kB inhibitors and their potential use in therapy of autoimmune diseases are critically discussed.
Keywords: ikk, autoimmune disease, inflammation, crohns disease, rheumatoid arthritis
Current Pharmaceutical Design
Title: The NF-kB Pathway as a Potential Target for Autoimmune Disease Therapy
Volume: 10 Issue: 23
Author(s): Susanne Bacher and M. Lienhard Schmitz
Affiliation:
Keywords: ikk, autoimmune disease, inflammation, crohns disease, rheumatoid arthritis
Abstract: A battery of proinflammatory agents triggers the activation of NF-κB. This inducible transcription factor participates in the expression of an exceptionally large number of target genes, many of them contributing to the regulation of innate and adaptive immunity. Since some target genes also function as NF-κB activators, activation of this transcription factor allows the establishment of a signal amplification loop. Dysregulation of the NF-κB system and hyperactivated expression of inflammatory mediators are often found in association with some autoimmune diseases, which occur upon mounting of the adaptive immune response against self-antigens. In this review we summarize the relevance of aberrant NF-κB signaling for the development and perpetuation of some autoimmune diseases such as rheumatoid arthritis, diabetes mellitus type 1 and Crohns disease. The assets and drawbacks of systemic or cell-type specific NF-kB inhibitors and their potential use in therapy of autoimmune diseases are critically discussed.
Export Options
About this article
Cite this article as:
Bacher Susanne and Schmitz Lienhard M., The NF-kB Pathway as a Potential Target for Autoimmune Disease Therapy, Current Pharmaceutical Design 2004; 10 (23) . https://dx.doi.org/10.2174/1381612043383584
DOI https://dx.doi.org/10.2174/1381612043383584 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HIV-Therapy Associated Lipodystrophy: Experimental and Clinical Evidence for the Pathogenesis and Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets Dronedarone – A New Alternative for Management of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery Therapeutic Approaches of Leptin in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Ezetimibe Therapy for Dyslipidemia: An Update
Current Pharmaceutical Design The Effectiveness of Nurse- and Pharmacist-Directed Care in Diabetes Disease Management:A Narrative Review
Current Diabetes Reviews Diagnosis and Management of Diabetes and the Relationship of dGlucose to Kidney Function
Current Diabetes Reviews Searching for Phytoinsulins as Cardiovascular Protector in Metabolic Syndrome
Current Pharmaceutical Design Regulation of Insulin Release at Pre-exocytotic Stages of the Secretory Process
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Vildagliptin Restores Renal Myogenic Function and Attenuates Renal Sclerosis Independently of Effects on Blood Glucose or Proteinuria in Zucker Diabetic Fatty Rat
Current Vascular Pharmacology Phenotypes and Enviromental Factors: Their Influence in PCOS
Current Pharmaceutical Design HbA1c, Fructosamine, and Glycated Albumin in the Detection of Dysglycaemic Conditions
Current Diabetes Reviews Surgical Complications of Hyperglycaemia
Current Diabetes Reviews Unfolded Protein Response as a Therapeutic Target in Cardiovascular Disease
Current Topics in Medicinal Chemistry Subject Index to Volume 2
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Nutritional Metabolomics: Lessons from Companion Animals
Current Metabolomics Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes
Current Chemical Biology Advances in Antidiabetic Drugs Targeting Insulin Secretion
Current Pharmaceutical Design Resveratrol Protects β Amyloid-Induced Oxidative Damage and Memory Associated Proteins in H19-7 Hippocampal Neuronal Cells
Current Alzheimer Research Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)